MedTrace Logo

The Use of Angiotensin Receptor Blockers and the Risk of Cancer

NCT02215733 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1165781

Last updated 2014-08-13

No results posted yet for this study

Summary

The primary objective of this study was to assess whether angiotensin blockers (ARBs) and telmisartan in particular, are associated with an increased overall risk of the four most common cancers, namely, lung, colorectal, breast and prostate cancers. A secondary objective was to explore these effects separately for each of the four cancers and in combination with angiotensin-converting-enzyme-inhibitors (ACEIs).

Conditions

Interventions

DRUG

ARB

other than telmisartan

DRUG

ACEI

DRUG

Beta-blockers

DRUG

Diuretics

DRUG

Telmisartan

Sponsors & Collaborators

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2012-02-29

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02215733 on ClinicalTrials.gov